Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phellodendron bawei (also known as Huangbai Bawei) is a Traditional Chinese and Mongolian Medicine formulation used primarily for the treatment of urogenital and inflammatory disorders. The formulation is characterized by the inclusion of eight medicinal ingredients (indicated by the term "Bawei"), with *Phellodendron amurense* (Amur cork tree bark) serving as the principal component. In clinical research, it is evaluated as an adjuvant therapy for patients with benign prostatic hyperplasia (BPH) to alleviate lower urinary tract symptoms (LUTS), improve sleep quality, and enhance medication compliance. Its therapeutic profile in traditional medicine involves clearing heat and drying dampness, which corresponds to anti-inflammatory and potentially prostate-modulating effects in modern clinical contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phellodendron bawei.